item management s discussion and analysis of financial condition and results of operations certain statements under item and item contained herein or as may otherwise be incorporated by reference herein constitute forward looking statements within the meaning of the private securities litigation reform act of forward looking statements include but are not limited to statements regarding future product development and related clinical trials and statements regarding future research and development 
such forward looking statements involve known and unknown risks  uncertainties and other factors which may cause the actual results  performance or achievements of the company  or industry results  to be materially different from any future results  performance or achievements expressed or implied by such forward looking statements 
such factors include  among other things  the following general economic and business conditions  competition  technological advances  ability to obtain rights to technology  ability to obtain and enforce patents  ability to commercialize and manufacture products  results of preclinical studies  results of research and development activities  business abilities and judgment of personnel  availability of qualified personnel  changes in  or failure to comply with  governmental regulations  ability to obtain adequate financing in the future  and other factors referenced herein 
all forward looking statements included in this document are based on information available to the company on the date hereof  and the company assumes no obligation to update any such forward looking statements 
accordingly  past results and trends should not be used by investors to anticipate future results or trends 
the following is a discussion of the historical consolidated financial condition and results of operations of novavax and its subsidiaries 
the discussion should be read in conjunction with the consolidated financial statements and notes thereto set forth in item to this report 
on december   the company s former parent  igi  inc  distributed its majority interest in novavax to the igi stockholders the distribution 
prior to the distribution  igi owned of the outstanding shares of the company  all of which were distributed to igi stockholders 
certain periods covered by the discussion below occurred when the company was a subsidiary of igi and may not be indicative of current or future performance 
results of operations the company has incurred net losses since its inception from the development of its technologies for human pharmaceuticals  vaccines and vaccine adjuvants 
novavax expects the losses to continue and to most likely increase in the near term  as it conducts additional human clinical trials and seeks regulatory approval for its product candidates 
the company also expects to continue to incur substantial operating losses over the extensive time period required to develop the company s products  or until such time as revenues  to offset the losses  are sufficient to fund its continuing operations 
until the second quarter of  the company had recorded revenues from two sources i research revenues from industry partners in consideration of either exclusive licenses or technology application reviews and ii royalty revenues that were attributable to product sales by igi 
revenues from the sale of scientific prototype vaccines and adjuvants have been recorded in the second  third and fourth quarters of and in each quarter of compared to the net loss of  for the year ended december  was  or  lower than the net loss of  for the year ended december  the net loss includes non cash compensation expense of  compared to  included in the net loss 
this compensation expense relates to the amortization of below market priced stock options and warrants issued at the time of the distribution 
other non cash charges include  of depreciation and patent amortization expense 
non cash charges in included  for the disposal of property and equipment and  of depreciation and patent amortization expense 
revenues of  were recognized during compared to  during the increase was due primarily to two contracts related to vaccine products  services and adjuvant technologies 
selling  general and administrative expenses include all costs associated with the marketing of the company s technology to potential industry partners and those activities associated with identifying additional sources of capital 
it also includes costs associated with management and administrative activities 
selling  general and administrative expenses were approximately  and  for the years ended december  and  respectively 
the increase of  was attributable to increased costs associated with securing strategic alliances and potential sources of financing as well as the increased staffing and infrastructure growth including the hiring of a new chief financial officer and chief executive officer 
research and development expenses include scientific staffing  supplies and other costs related to the ongoing development of the novavax technologies as well as the development of the company s three lead product candidates 
research and development expenses were approximately  and  for the years ended december  and  respectively 
although such expenses have decreased by  this change is primarily caused by the net decrease in the amortization of below market priced stock options issued at the time of the distribution of  and the non recurring charge of  for the disposal of assets in research and development expenses  before these items were  and  for and after considering the impact of these aforementioned non cash expenses  research and development costs increased by  the increase was primarily due to the number of product candidates in clinical trials and the growth of the underlying research and development infrastructure including facility expansion 
interest income was approximately  and  for the years ended december  and  respectively 
the increase in net interest income was a direct result of an increase in the average cash balances on hand throughout the year 
compared to the net loss of  for the year ended december  was  or  lower than the net loss of  for the year ended december  the net loss includes  compared to  included in the net loss  of non cash compensation expense 
other non cash charges include  for the disposal of property and equipment and  of depreciation and patent amortization expense 
non cash charges of  for depreciation and patent amortization have been included in the expense 
revenues of  were recognized during the year ended december  from the sale of scientific prototype vaccines and adjuvants 
novavax earned royalties from igi of of licensed product sales  or  in the year ended december  total operating expenses were  in  decreasing  or  from the  incurred in reduced cash resources caused the company to reduce spending and achieve other efficiencies including a refocus of its efforts on the development of its three lead product candidates in connection with fda human clinical trials 
total selling  general and administrative expenses were  and  for the years ended december  and  respectively 
costs associated with the distribution are included in the expenses 
nonrecurring charges of  were incurred through june  for transitional services provided by igi 
the agreement providing these services terminated on june  and no additional charges have been recorded 
certain costs included in the expenses were estimates allocated from igi  based on novavax being a separate public company  and may not compare with the actual costs novavax incurred in these estimated costs were  for the year ended december  research and development expenses were  and  for the years ended december  and  respectively 
the expenses include non cash charges of  compared to  in  related to the amortization of below market priced stock options issued at the time of the distribution  and non cash charges of  for the disposal of property and equipment related to the closing of one of the novavax subsidiaries laboratory 
net interest income of  was recorded during the twelve months ended december   compared with net interest expense of  for the same period ended december   that was charged to novavax by igi for borrowings and notes due to igi through the date of the distribution to fund operating losses  capital equipment purchases and patent costs 
in connection with the filing of the company s tax return during  it was determined that the company had an alternative minimum tax liability resulting from the cash received from igi in return for the license 
net income tax expense of  for is attributable to the alternative minimum tax calculation 
liquidity and capital resources novavax s capital requirements depend on numerous factors  including but not limited to the progress of its research and development programs  the progress of preclinical and clinical testing  the time and costs involved in obtaining regulatory approvals  the costs of filing  prosecuting  defending and enforcing any patent claims and other intellectual property rights  competing technological and market developments  and changes in novavax s development of commercialization activities and arrangements 
during  the company moved three product candidates into clinical trials in less than one year 
this rapid development prompted the need for expansion in late on october   the company completed the relocation of its administrative offices and pharmaceutical laboratories to a leased facility in columbia  maryland 
future activities to establish commercial scale manufacturing capabilities are subject to the company s ability to raise funds through equity financing  or collaborative arrangements with corporate partners 
novavax s future growth will depend on its ability to commercialize its novavax technologies for human pharmaceutical applications 
net cash used in for operating activities was  from the date of the distribution  novavax has conducted its operations with approximately  paid by igi under the igi license agreement along with net proceeds from several financing transactions completed and described herein 
additionally the company has received sources of cash from the sale of scientific prototype vaccines and adjuvants and from the exercise of stock options 
on october   novavax received  net of all transaction costs  from the sale of  common shares that were privately placed with accredited institutional investors by vector securities international  inc on february   novavax signed a definitive agreement to privately place  common shares with anaconda opportunity fund  lp  an accredited institutional investor  at an aggregate price of  as part of the transaction  novavax also granted warrants to purchase an additional  shares at a price of per share and  shares at a price of per share 
the warrants have a three year term 
the transaction was closed march  with net proceeds of  on january   the company entered into subscription agreements with each of four purchasers to effectuate the private placement of  share of series a custom convertible preferred stock  
par value per share the series a preferred stock 
the closing occurred on january  the issuance date at an aggregate purchase price of  the company received the proceeds therefor and paid diaz altschul  llc a fee of  in consideration for its services as placement agent 
the series a preferred stock is convertible into shares of common stock at a conversion price equal to i during a period of days following the issuance date  of the average of the two lowest consecutive trade prices of the common stock as reported on the american stock exchange for the trading days immediately preceding the conversion date the two day average trading price or ii during the period on and after the date which is days after the issuance date  of the two day average trading price the conversion price 
from the issuance date  there is a ceiling price of and within the first days after the issuance date  the conversion price has applicable floor prices  ranging from to  based on conversion dates 
the maximum number of shares as measured by the conversion terms most beneficial to the holders of the series a preferred stock at the time of closing results in a deemed dividend in the amount of  which will be recorded in the first quarter of as of december   novavax estimates that the money received from the most recent sale of the privately placed preferred stock  and its existing cash resources will be sufficient to finance its operations at current and projected levels of development activity for approximately to months 
on december   the company had  in cash  cash equivalents and marketable securities on hand 
past spending levels are not necessarily indicative of future spending 
future expenditures for product development  especially relating to outside testing and human clinical trials  are discretionary and  accordingly  can be adjusted to available cash 
moreover  the company will seek to establish one or more collaborations with industry partners to defray the costs of clinical trials and other related activities 
novavax will also seek to obtain additional funds through public or private equity or debt financings  collaborative arrangements with pharmaceutical companies or from other sources 
there can be no assurance that additional funding or bank financing will be available at all or on acceptable terms to permit successful commercialization of novavax s technologies and products 
if adequate funds are not available  novavax may be required to significantly delay  reduce the scope of or eliminate one or more of its research or development programs  or seek alternative measures including arrangements with collaborative partners or others that may require novavax to relinquish rights to certain of its technologies  product candidates or products 
item a 
quantitative and qualitative disclosures about market risk s not applicable 

